Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which insulin dosing method keeps hospital blood sugar in check?

NCT ID NCT07808398

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study tests two common methods for calculating mealtime insulin doses in hospitalized adults with type 2 diabetes. One method, carbohydrate counting, adjusts the insulin dose based on the grams of carbs a patient actually eats. The other uses a fixed dose that changes only with the percentage of the meal consumed. Researchers will compare how well each method keeps blood glucose within a target range of 100 to 180 mg/dL during the hospital stay. The goal is to find which approach offers better glucose control and fewer dangerous highs or lows.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two insulin dosing strategies: carbohydrate-counting-based rapid-acting insulin dosing and flexible fixed mealtime rapid-acting insulin dosing based on percentage of meal consumed
What this could lead to
If one strategy works better, hospitals could adopt it to keep patients' blood sugar in a safer range during stays, reducing complications.
What could go wrong
The trial is early and results may not apply to all patients. Both strategies are already used, so the difference might be small, and measuring glucose in real-world hospital settings can be imprecise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Adults ≥18 years * Admitted to non-ICU units * Require scheduled prandial insulin as part of basal-bolus insulin therapy with CC. Exclusion criteria * History of type 1 DM * History of total pancreatectomy * Use of pre-admission CC for prandial insulin administration * Critical illness requiring ICU admission at time of recruitment. * Admission to psychiatry services * Pregnancy * All forms of enteral/tube feeding or parenteral nutrition at recruitment * Observation status at time of recruitment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 2 on insulin are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 2 on insulin Hyperglycemia due to type 2 diabetes mellitus Hypoglycemia (diabetic)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.